Abstract:Liposomal spherical nucleic acids (L-SNAs) show significant promise as cancer immunotherapeutics. L-SNAs are highly modular nanoscale assemblies defined by a dense, upright radial arrangement of oligonucleotides around a liposomal core. Herein, we establish a set of L-SNA design rules by studying the biological and immunological properties of L-SNAs as a function of liposome composition. To achieve this, we synthesized liposomes where the lipid phosphatidylcholine headgroup was held constant, while the diacyl lipid tail chain length and degree of saturation were varied, using either 1,2-dioleylphosphatidylcholine (DOPC), 1,2-dimyristoyl-phosphatidylcholine (DMPC), 1,2-dipalmitoylphosphatidylcholine (DPPC), or 1,2-distearoyl-phosphatidylcholine (DSPC). These studies show that the identity of the constituent lipid dictates the DNA loading, cellular uptake, serum stability, in vitro immunostimulatory activity, and in vivo lymph node accumulation of the L-SNA. Furthermore, in the 4T1 mouse model of triple-negative breast cancer (TNBC), the subcutaneous administration of immunostimulatory L-SNAs synthesized with DPPC significantly decreases the production of lung metastases and delays tumor growth as compared to L-SNAs synthesized using DOPC, due to the enhanced stability of L-SNAs synthesized with DPPC over those synthesized with DOPC. Moreover, the inclusion of cell lysates derived from Py8119 TNBC cells as antigen sources in L-SNAs leads to a significant increase in antitumor efficacy in the Py8119 model when lysates are encapsulated in the cores of L-SNAs synthesized with DPPC rather than DOPC, presumably due to increased codelivery of adjuvant and antigen to dendritic cells in vivo. This difference is further amplified when using lysates from oxidized Py8119 cells as a more potent antigen source, revealing synergy between the lysate preparation method and liposome composition in synthesizing immunotherapeutic L-SNAs. Together, this work shows that the biological properties and immunomodulatory activity of L-SNAs can be modulated by exchanging liposome components, providing another handle for the rational design of nanoscale immunotherapeutics.The molecular identity of the lipids that comprise liposomal spherical nucleic acids modulates their biological properties and provides a handle for their rational design as cancer immunotherapeutics.This article has not yet been cited by other publications.

Tuning DNA Dissociation from Spherical Nucleic Acids for Enhanced Immunostimulation

Enhancing the Stability and Immunomodulatory Activity of Liposomal Spherical Nucleic Acids Through Lipid-Tail DNA Modifications.

Impact of Liposomal Spherical Nucleic Acid Structure on Immunotherapeutic Function

Immunomodulatory Spherical Nucleic Acids*

Chemically Tuning the Antigen Release Kinetics from Spherical Nucleic Acids Maximizes Immune Stimulation

Cross-Linked Micellar Spherical Nucleic Acids From Thermoresponsive Templates

Enhanced Immunostimulatory Activity of a Cytosine-Phosphate-Guanosine Immunomodulator by the Assembly of Polymer DNA Wires and Spheres

A Spherical Nucleic Acid Platform Based on Self-Assembled DNA Biopolymer for High-Performance Cancer Therapy

Synergistic Immunostimulation through the Dual Activation of Toll-like Receptor 3/9 with Spherical Nucleic Acids

Spherical Nucleic Acids: Adding a New Dimension to Nucleic Acids and Clinical Chemistry

Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy

Abstract IA16: Spherical Nucleic Acids As a Powerful New Platform for Cancer Immunotherapy

From Structure to Application: The Evolutionary Trajectory of Spherical Nucleic Acids

Design and Characterization of Compact, Programmable, Multistranded Nonimmunostimulatory Nucleic Acid Nanoparticles Suitable for Biomedical Applications

Defining the Design Parameters for in Vivo Enzyme Delivery Through Protein Spherical Nucleic Acids.

Spherical Nucleic Acids with Tailored and Active Protein Coronae

Expanding Structural Space for Immunomodulatory Nucleic Acid Nanoparticles (Nanps) via Spatial Arrangement of Their Therapeutic Moieties

Nucleic Acid Nanostructure Assisted Immune Modulation

Novel T Cell Therapy Using Spherical Nucleic Acids

Development of Spherical Nucleic Acids for Prostate Cancer Immunotherapy.

Structure-Dependent Biodistribution of Liposomal Spherical Nucleic Acids